Sumanirole

Sumanirole (PNU-95,666) is a highly selective D₂ receptor full agonist, the first of its kind to be discovered.^[1][2][3] It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use^[4][5] it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D₂-linked (vs. D₁-, D₃-, D₄-, and D₅-linked) mechanism of action.^[3]

Other namesPNU-95,666

ATC code

• none

CAS Number

• 179386-43-7
  179386-44-8 (maleate)

PubChem CID

• 9818479

Quick facts Clinical data, Other names ...

Sumanirole

Clinical data
Other names	PNU-95,666
ATC code	none
Identifiers
IUPAC name (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one
CAS Number	179386-43-7 179386-44-8 (maleate)
PubChem CID	9818479
IUPHAR/BPS	3949
ChemSpider	7994229
UNII	3E93IV1U45
ChEMBL	ChEMBL419792
CompTox Dashboard (EPA)	DTXSID00870144
Chemical and physical data
Formula	C11H13N3O
Molar mass	203.245 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23

Close

In 2004, Pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.^[6]